Q-omics provides the consensus-scored TRIM64EP profile across patient tissues and cancer cell-line models. TRIM64EP expression is associated with patient survival in 4 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TRIM64EP is differentially expressed in 1, with the highest sampling consensus in LUSC. Additionally, TRIM64EP RNA expression shows 5,018 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KIRC, LUSC, and STAD as cancer lineages where TRIM64EP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRIM64EP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRIM64EP survival associations across molecular data types. TRIM64EP RNA expression shows survival associations in the most cancer types (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRIM64EP RNA expression–survival associations across cancer types. High TRIM64EP expression shows unfavorable associations in KIRC, BRCA, TGCT and SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .011). Together, the overview and detailed table identify KIRC as the clearest survival context for TRIM64EP RNA expression.
This table summarizes TRIM64EP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for TRIM64EP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRIM64EP shows higher tumor expression in LUSC. The LUSC box plot shows higher TRIM64EP RNA expression in tumor versus normal tissue (log2 FC = +0.005, t-test p = .030).
This table shows molecular features associated with TRIM64EP in patient tissues and cancer cell lines. In patient samples, TRIM64EP shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
